NCT06413355View on ClinicalTrials.gov

FAPI-74 PET/CT in Adults with Fibrosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 16, 2024

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2027

Conditions
Fibrosis (Morphologic Abnormality)
Interventions
DRUG

[F-18]-FAPI-74

A positron-emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo expression of FAP with positron emission tomography (PET/CT).

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER